Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam for inhalation in non-CF bronchiectasis
NCT01313624Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2011
- Primary completion
- Mar 2013
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of aztreonam in bronchiectasis and endobronchial infection (2 arms), sponsored by Gilead Sciences. Primary endpoint: Change in QOL-B Respiratory Symptoms Score at 28 days. Started Apr 2011; status: completed.
02
Drugs
aztreonam
03
Conditions
bronchiectasisendobronchial infection
Beyond the preview
Go deeper on NCT01313624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313624.